Review of Pediatric Tuberculosis in the Aftermath of COVID-19

Clin Pract. 2022 Sep 11;12(5):738-754. doi: 10.3390/clinpract12050077.

Abstract

In 2014, the World Health Organization developed the End Tuberculosis Strategy with the goal of a 95% reduction in deaths from tuberculosis (TB) by 2035. The start of the COVID-19 pandemic and global lockdown has had a major impact on TB awareness, screening, diagnosis, and prompt initiation of treatment, inevitably leading to a significant setback. We explore pediatric tuberculosis through the lens of the COVID-19 era, investigating how COVID-19 has impacted pediatric TB cases in different regions of the world and what the implications are for management moving forward to mitigate these effects. Furthermore, in light of recent findings showing how exposed infants and children are at higher risk than we thought of contracting the disease, greater attention and resources are needed to prevent further downward trends.

Keywords: COVID-19; SARS-CoV-2; immunology; pediatrics; prevention; tuberculosis.

Publication types

  • Review

Grants and funding

This research received no external funding.